Alx Oncology Holdings (ALXO) Capital Expenditures (2019 - 2026)
Alx Oncology Holdings recorded quarterly Capital Expenditures of $50000.0 in Q1 2026, up 2.04% quarter-over-quarter from $49000.0 in Q4 2025, and down 16.67% year-over-year from $60000.0 in Q1 2025.
Alx Oncology Holdings' Capital Expenditures history runs 8 years deep, the most recent figure standing at $50000.0 for Q1 2026.
- In Q1 2026, Capital Expenditures fell 16.67% year-over-year to $50000.0; the TTM figure through Mar 2026 stood at $202000.0 (down 43.73% YoY), while the FY2025 annual figure was $212000.0, down 52.57% from the prior year.
- Capital Expenditures came in at $50000.0 for Q1 2026 at Alx Oncology Holdings, up from $49000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $1.7 million in Q2 2023 to a low of -$1.3 million in Q3 2023.
- A 5-year average of $200588.2 and a median of $148000.0 in 2023 frame the typical range for Capital Expenditures.
- Across the five-year window, Capital Expenditures soared 8314.29% in 2022 and plunged 778.65% in 2023, its largest moves.
- Alx Oncology Holdings' Capital Expenditures stood at $389000.0 in 2022, then tumbled by 61.95% to $148000.0 in 2023, then slumped by 59.46% to $60000.0 in 2024, then declined by 18.33% to $49000.0 in 2025, then advanced by 2.04% to $50000.0 in 2026.
- According to Business Quant data, Capital Expenditures over the past three periods registered $50000.0, $49000.0, and $56000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 133.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 230.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 21.83 Mn |
| 10 | Alx Oncology Holdings | 189.80 Mn | 49.48 Mn | - | 50,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 50,000.00 |
| Mar 31, 2026 | 50,000.00 |
| Dec 31, 2025 | 49,000.00 |
| Dec 31, 2025 | 49,000.00 |
| Sep 30, 2025 | 56,000.00 |
| Sep 30, 2025 | 56,000.00 |
| Jun 30, 2025 | 47,000.00 |
| Jun 30, 2025 | 47,000.00 |
| Mar 31, 2025 | 60,000.00 |
| Mar 31, 2025 | 60,000.00 |
| Dec 31, 2024 | 60,000.00 |
| Dec 31, 2024 | 60,000.00 |
| Sep 30, 2024 | 149,000.00 |
| Sep 30, 2024 | 149,000.00 |
| Jun 30, 2024 | 90,000.00 |
| Jun 30, 2024 | 90,000.00 |
| Mar 31, 2024 | 148,000.00 |
| Mar 31, 2024 | 148,000.00 |
| Dec 31, 2023 | 148,000.00 |
| Dec 31, 2023 | 148,000.00 |
| Sep 30, 2023 | -1.30 Mn |
| Sep 30, 2023 | -1.30 Mn |
| Jun 30, 2023 | 1.74 Mn |
| Jun 30, 2023 | 1.74 Mn |
| Mar 31, 2023 | 690,000.00 |
| Mar 31, 2023 | 690,000.00 |
| Dec 31, 2022 | 389,000.00 |
| Dec 31, 2022 | 389,000.00 |
| Sep 30, 2022 | 192,000.00 |
| Sep 30, 2022 | 192,000.00 |
| Jun 30, 2022 | 257,000.00 |
| Jun 30, 2022 | 257,000.00 |
| Mar 31, 2022 | 589,000.00 |
| Mar 31, 2022 | 589,000.00 |
| Dec 31, 2021 | 261,000.00 |
| Dec 31, 2021 | 261,000.00 |
| Sep 30, 2021 | 398,000.00 |
| Sep 30, 2021 | 398,000.00 |
| Mar 31, 2021 | 7,000.00 |
| Mar 31, 2021 | 7,000.00 |
| Dec 31, 2020 | 11,000.00 |
| Dec 31, 2020 | 11,000.00 |
| Sep 30, 2020 | -1.93 Mn |
| Sep 30, 2020 | -1.93 Mn |
| Jun 30, 2020 | 1.94 Mn |
| Jun 30, 2020 | 1.94 Mn |
| Mar 31, 2020 | 10,000.00 |
| Mar 31, 2020 | 10,000.00 |
| Dec 31, 2019 | -62,000.00 |
| Dec 31, 2019 | -62,000.00 |